Has Verachai Lohavichan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,774 in general payments to Verachai Lohavichan, MD across 57 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Verachai Lohavichan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Verachai Lohavichan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Verachai Lohavichan, MD

Nephrology · Charlotte, NCNPI 1568428159

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (56.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 40.4% of the total. Reporting peaked in 2023 at $1,434 and has fallen 87.3% since, to $182 in 2025.

$3,774in general payments, 2019–2025

Across 57 payments — averaging $66.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Bard Peripheral Vascular, Inc.$2K
Medtronic$1K
W. L. Gore & Associates, Inc.$545
Calliditas Therapeutics US Inc.$125
Nxstage Medical, Inc.$66
Boehringer Ingelheim$42
plus $152 from 7 others

$49,111in research payments, 2019–2025

Across 3 payments — averaging $16,370 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$49K

What the payments were for

Travel & lodging$1,62343%
Food & beverage$2,11556%
Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Bard Peripheral Vascular, Inc.	29	$1,523
Medtronic	10	$1,322
W. L. Gore & Associates, Inc.	6	$545
Calliditas Therapeutics US Inc.	1	$125
Nxstage Medical, Inc.	1	$66
Boehringer Ingelheim	2	$42
Cordis US CORP.	1	$33
Philips North America LLC	2	$29
Ardelyx, Inc.	1	$23
Venturemed Group, Inc.	1	$17
Travere Therapeutics, Inc.	1	$17
Covidien LP	1	$16
Acelrx Pharmaceuticals, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ELLIPSYS VASCULAR ACCESS SYSTEM$1,100
GORE VIABAHN Endoprosthesis with Heparin$380
Pristine$133
TARPEYO$125
VIABAHN Endoprosthesis with Heparin Bioactive Surface$125

How this compares

$3,774 in reported general payments places this provider in the 70th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina →

Medicare billing

Part B allowed, 2024

$117,494

Medicare patients

398

Services billed

2,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
FarxigaDapagliflozin Propanediol	24	$16,162
Sevelamer Carbonate	15	$1,314
Amlodipine Besylate	30	$151
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	13	$109
ClopidogrelClopidogrel Bisulfate	26	$95
Lactulose	19	$85
Losartan Potassium	17	$80
Hydralazine Hcl	12	$62
Furosemide	13	$60
Lisinopril	12	$58
Prednisone	13	$43

Paid to pharmacies, not to this prescriber.

Other nephrology in Charlotte

Michael EtomiCharlotte$212K
Tomas Guerrero NunezCharlotte$6K
George HartCharlotte$6K
Gregory GreenwoodWinston-Salem$947K
William KendrickGreenville$125K
Jason EckelCary$123K
Raven VooraSanford$111K
Nam VoAsheville$89K
Jennifer StoddardPinehurst$77K
Barry FreedmanWinston Salem$67K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →